- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 795843, 9 pages
The Components of Flemingia macrophylla Attenuate Amyloid β-Protein Accumulation by Regulating Amyloid β-Protein Metabolic Pathway
1Division of Medicinal Chemistry, National Research Institute of Chinese Medicine, Taipei 112, Taiwan
2Institute of Neuroscience, National Yang-Ming University, Taipei 112, Taiwan
3Institute of Biopharmaceutical Science, National Yang-Ming University, Taipei 112, Taiwan
4Division of Basic Chinese Medicine, National Research Institute of Chinese Medicine, Taipei 112, Taiwan
Received 10 January 2012; Revised 6 March 2012; Accepted 13 March 2012
Academic Editor: Karl Wah-Keung Tsim
Copyright © 2012 Yun-Lian Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Flemingia macrophylla (Leguminosae) is a popular traditional remedy used in Taiwan as anti-inflammatory, promoting blood circulation and antidiabetes agent. Recent study also suggested its neuroprotective activity against Alzheimer's disease. Therefore, the effects of F. macrophylla on Aβ production and degradation were studied. The effect of F. macrophylla on Aβ metabolism was detected using the cultured mouse neuroblastoma cells N2a transfected with human Swedish mutant APP (swAPP-N2a cells). The effects on Aβ degradation were evaluated on a cell-free system. An ELISA assay was applied to detect the level of Aβ1-40 and Aβ1-42. Western blots assay was employed to measure the levels of soluble amyloid precursor protein and insulin degrading enzyme (IDE). Three fractions of F. macrophylla modified Aβ accumulation by both inhibiting β-secretase and activating IDE. Three flavonoids modified Aβ accumulation by activating IDE. The activated IDE pool by the flavonoids was distinctly regulated by bacitracin (an IDE inhibitor). Furthermore, flavonoid 94-18-13 also modulates Aβ accumulation by enhancing IDE expression. In conclusion, the components of F. macrophylla possess the potential for developing new therapeutic drugs for Alzheimer's disease.
Flemingia macrophylla (Leguminosae) is a popular traditional remedy used in Taiwan  and India . The stems or leaves have been used as an anti-inflammatory, blood circulation promotion and antidiabetic agent, all of which were relevant to the pathogenesis of Alzheimer’s disease (AD). Recent research has suggested its neuroprotective activity against amyloid β (Aβ) , hepatoprotective activity , antiinflammatory activity , and antiosteoporosis activity .
AD is a complex mental illness characterized by the accumulation of extracellular senile plaques and intracellular neurofibrillary tangles. Senile plaques are composed of deposited Aβ, derived from the processing of amyloid precursor protein (APP) by two enzymes: β-site APP cleaving enzyme (BACE or β-secretase) and γ-secretase . According to the amyloid hypothesis, abnormal accumulation of Aβ in the brain is the primary causative factor contributing to AD pathogenesis, whereby the disease process is believed to result from an imbalance between Aβ production (anabolic activity) and clearance (catabolic activity) [8–10]. APP molecules are cleaved by secretases at the cell surface, the Golgi complex, and along the endosomal/lysosomal pathway [11, 12]. Most cell surface β-secretase is reinternalized into early endosomal compartments, from where it can be recycled back to the cell surface or later be redirected to endosomal/lysosomal compartments and/or to the trans-Golgi . It is generally believed that removal of Aβ from the brain might be of great therapeutic benefit . Consequently, therapeutic strategies aiming to decrease Aβ levels, such as inhibition of either β-secretase or γ-secretase and Aβ immunization, are currently a major focus of AD research [15–17]. Much more attention has been paid to abnormal Aβ production, but recently, the role of Aβ degradation in Aβ homoeostasis has been increasingly recognized, as several enzymes that degrade Aβ have been identified, such as insulin degrading enzyme (IDE), neprilysin (NEP), and matrix metalloproteins (MMPs) .
Clinical and epidemiological studies have found that type 2 diabetes and hyperinsulinemia increased the risk of developing AD, and the link between these two diseases may be IDE [19, 20]. IDE is a zinc metalloendopeptidase that is highly expressed in the liver, testis, muscle, and brain. Although it is predominantly cytosolic, a secreted form of IDE in extracellular compartments such as cerebrospinal fluid was also identified . IDE degrades a wide range of substrates that include insulin, amylin, insulin-like growth factors, and Aβ . Furthermore, previous work has reported that the IDE level in AD is reduced .
In this study, we investigate the effect of F. macrophylla extracts or isolated pure compounds on Aβ accumulation and found that they decrease extracellular accumulation of Aβ1-40 in the cultured mouse neuroblastoma cells N2a transfected with human Swedish mutant APP (swAPP-N2a cells) by inhibiting β-secretase or enhancing Aβ degradation.
Medium for cell culture, heparin, Lipofectamine, and human β amyloid 1-40 and 1-42 kits were purchased from Invitrogen (Carlsbad, CA, USA). Mouse anti-actin antibody and anti-IDE polyclonal antibody, rabbit polyclonal anti-APP (KPI domain) antibody, and synthetic Aβ1-40 were purchased from Millipore (Billerica, MA, USA). Anti-Aβ1-17 antibody (clone 6E10) was from Signet (Dedham, MA). Enhanced chemiluminescence detection reagents, anti-rabbit and anti-mouse IgG antibody conjugated with horseradish peroxidase were obtained from GE Healthcare (Buckinghamshire, UK). Insulin, progesterone, putrescine, sodium selenite, and transferrin were purchased from Sigma (St. Louis, MO, USA). All other reagents were purchased from Sigma (St. Louis, MO, USA) or Merck (Darmstadt, Germany).
2.2. Plant Material, Extraction, and Isolation
The aerial parts of F. macrophylla were collected from Kaohsiung County, Taiwan in May, 2002. The plant was identified by Mr. Jun-Chih Ou, former associate investigator of National Research Institute of Chinese Medicine, and comparison with the voucher specimens was deposited earlier at the Herbarium of the Department of Botany, National Taiwan University, Taipei, Taiwan (no. TAI219262, April, 1988). The extraction and isolation of each fraction for this assay is listed in Table 1, and the structure and chemical name of the flavonoids isolated from F. macrophylla were displayed in Figure 1.
2.3. Cell Culture and Transfection
Neuro-2a (N2a) cells were cultured in minimal essential medium (MEM) containing 10% fetal bovine serum (FBS). Confluent 90% N2a cells were transfected with plasmid containing human Swedish mutant of amyloid precursor protein (pCGR/APP770) by using Lipofectamine 2000. After transfection for 6 h, the cells were incubated with chemical defined medium (DMEM/F12 medium containing 5 mM Hepes pH 7.4, 0.6% glucose, 2.5 mM glutamine, 3 mM NaHCO3, 100 μg/mL, transferring, 20 nM progesterone, 60 μM putrescine, 30 nM sodium selenite, 2 μg/mL heparin, and 100 nM insulin) for 20 h. For treatment with cells, the fractions or flavanoids of F. macrophylla were introduced into the chemical defined medium.
2.4. MTT Assay
The reduction of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) was used to evaluate cell viability. Cells were incubated with 0.5 mg/mL MTT for 1 h. The formazan particles were dissolved with DMSO. OD600 nm was measured using an ELISA reader.
2.5. The Cell-Free Assay of Aβ1-40 Degradation
The conditioned medium of N2a cells containing the proteases to degrade Aβ was collected and used for the cell-free assay of Aβ degradation. Ten ng of synthetic Aβ1-40 (Invitrogen, 03-138) were added into 300 μL N2a-conditioned medium containing various reagents and incubated at 37°C for 24 h. The remaining Aβ were then quantified by ELISA assay kit.
2.6. Quantification of Aβ1-40 in Cells and Culture Medium
After treatment, culture media and cell were collected separately and subjected to determining the levels of Aβ1-40 using assay kits. The detailed experiments were performed according to the manufacturer’s protocol.
After treatment, culture media were collected and cells were washed with ice-cold phosphate buffered saline (PBS) three times. Cells were harvested in lysis buffer (50 mM Hepes pH7.5, 2.5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 5 μg/mL aprotinin, and 10 μg/mL leupeptin), and cell lysates were prepared. Equal protein amounts of cell lysate and equal volume of culture medium were subjected to SDS-polyacrylamide gel electrophoresis and immunoblotting. Fujifilm LAS-3000 (Tokyo, Japan) was used to detect and quantify the immunoreactive protein.
2.8. Statistical Analysis
Results are expressed as mean ± SD and were analyzed by ANOVA with post hoc multiple comparisons with a Bonferroni test.
3.1. The Effects of Insulin and Bacitracin on Aβ1-40 Level in swAPP-N2a Cells Culture
To determine the importance of IDE activity on the levels of both extracellular and intracellular Aβ1-40 in swAPP-N2a cell culture, various concentrations of insulin (the substrate of IDE) and/or 2 nM bacitracin (a competitive inhibitor of IDE) were subjected into swAPP-N2a cell culture, and the Aβ1-40 accumulation was assayed. The results showed that insulin promotes Aβ1-40 accumulation in a concentration-dependent manner. Extracellular Aβ1-40 was hardly detected (i.e., ng/mL) in the culture medium without containing insulin. Insulin at 10, 100, 1000, and 4200 nM increased the level of extracellular Aβ1-40 to ng/mL, ng/mL, ng/mL, and ng/mL, respectively (Figure 2(a)). The results suggested that about 26 ng/mL of extracellular Aβ1-40 in the cultured medium regulated by insulin sensitive peptidase(s), including IDE. Therefore, bacitracin was employed to verify the IDE-sensitive pool of extracellular Aβ1-40 in the cultured medium. The results showed that 2 nM bacitracin increased the level of extracellular Aβ1-40 to ng/mL (Figure 2(a)), and higher concentration of bacitracin did not significantly enhance this effect, suggesting that about 11 ng/mL of extracellular Aβ1-40 in the cultured medium was regulated by IDE.
Insulin may regulate the extracellular Aβ1-40 by enhancing exocytosis of the intracellular Aβ1-40. Therefore, the level of intracellular Aβ1-40 was assayed. The results showed that the level of intracellular Aβ1-40 was concentration dependently reduced by insulin, but not by bacitracin (Figure 2(b)). The results suggested that insulin may promote the level of extracellular Aβ1-40 by inhibiting IDE and by accelerating the exocytosis of intracellular Aβ1-40. Alternately, bacitracin did not affect the exocytosis of intracellular Aβ1-40. The similar effects of insulin and bacitracin were found on Aβ1-42 (data not shown).
3.2. The Effects of Insulin and Bacitracin on the Degradation of Synthetic Aβ1-40 in the N2a-Conditioned Medium
For bypassing the involvement of Aβ anabolic and trafficking pathway, a cell-free Aβ degradation assay using N2a cell-conditioned medium as the source of secreted protease and the synthetic Aβ1-40 was employed as the substrate. The results showed that Aβ degradation was inhibited by insulin in a concentration-dependent manner (Figure 3). The added synthetic Aβ1-40 (10 ng) was degraded to ng in the conditioned medium without containing insulin, and 10, 100, and 1000 nM insulin increased the level of remaining Aβ1-40 to ng, ng, and ng, respectively, indicating that the degradation of 10 ng Aβ was completely abolished by 1 μM insulin (Figure 3). Treatment with 2 nM, 5 nM bacitracin, or 2 nM bacitracin combined with 100 nM insulin increased the remaining level of Aβ1-40 to , , and ng, respectively (Figure 3), suggesting a synergism of insulin and bacitracin on inhibiting Aβ degradation.
3.3. The Effects of the Fractions and Flavonoids Isolated from F. macrophylla on the Level of Aβ1-40
To determine the effects of the fractions and flavonoids isolated from F. macrophylla on the level of extracellular Aβ1-40, the cell toxicity of the fractions and flavonoids was detected, and was then the subtoxic concentration (STC) of the fractions and flavonoids was subjected into the extracellular Aβ1-40 accumulation assay. The results indicated that five highly polar fractions (i.e., EtOH, H2O, H75M, B50M, and B75M) attenuated the accumulation of medial Aβ1-40 by more than 50% (Table 2). Among the lesser polar fractions, EA-74 is the most effective fraction which attenuated the accumulation of medial Aβ1-40 to % of control (Table 2). Three flavonoids (i.e., 49-2, 52-11, and 94-18-13) attenuated the accumulation of extracellular Aβ1-40 by more than 30% (Table 3).
The effects of the fractions and flavonoids on the intracellular Aβ1-40 accumulation were further evaluated. The result showed that the fraction H2O, H75M, and B75M elevated the intracellular level of Aβ1-40 to , , and % of the control, respectively, and the fraction EtOH, B50M, and EA-74 and the flavonoid 49-2, 52-11, and 94-18-13 did not exert significant effects on the intracellular Aβ1-40 accumulation (Tables 2 and 3). Those were therefore selected for further investigation.
3.4. The Effects of the Fractions and Flavonoids Isolated from F. macrophylla on the Aβ1-40 Degradation in the N2a-Conditioned Medium
The fraction EtOH, EA-47, B50M, and flavonoid 49-3, 52-11, and 94-19-13 decreased the remaining synthetic Aβ1-40 to %, %, %, %, %, and % of the control, respectively (Figure 4). The results suggesting that the fractions and flavonoids may ameliorate Aβ accumulation by promoting Aβ degradation. The similar effects were found on Aβ1-42 (data not shown).
3.5. The Level of Secreted IDE Was Promoted by Flavonoid 94-18-13
Treatment with the fraction B50M, EA-74, and flavonoid 49-2, 52-11, and 94-18-13 attenuated the level of cellular IDE by about 20%, whereas the fraction EtOH failed to show significant effect on the level of cellular IDE (Figure 5). Treatment with the faction B50M and EA-74 eliminated the level of medial IDE by and %, respectively. On the contrary, flavonoid 94-18-13 increased the level of medial IDE to % of the control. The result suggested that only flavonoid 94-18-13 may accelerate Aβ degradation by promoting IDE expression. The change in enzyme activity may also be involved although it is not detected in this study.
3.6. The Recovery Effect of Bacitracin on the Treatment-Reduced Accumulation of Extracellular Aβ1-40
The promoting activity of the fractions and flavonoids on Aβ degradation by IDE may include bacitracin-sensitive and -insensitive pools. The bacitracin-sensitive pools in the cultures treated with the fraction EtOH, EA-74, B50M, and flavonoid 94-19-13 were 10.71, 10.83, 11.35, and 11.29 ng/mL, respectively (Figure 6). The results suggested that these treatments did not affect the bacitracin-sensitive pool. The bacitracin-sensitive pools in the cultures treated with the flavonoid 49-3 and 52-11 were 7.18 and 14.05 ng/mL, suggesting that flavonoid 49-3 and 52-11 reduce and enhance the bacitracin-sensitive pool, respectively.
3.7. The Level of Soluble APPβ Was Decreased by the Fractions of F. macrophylla
The anabolic pathway of Aβ may also be affected by the fractions of F. macrophylla which resulted in the decrease of extracellular Aβ. Two categories of soluble APP (sAPP) including α-secretase-derived sAPP (sAPPα) and β-secretase-derived sAPP (sAPPβ) may be detected in the swAPP-N2a-conditioned medium. Two antibodies were used to detect these two sAPPs. The anti-Aβ1-17 (6E10) antibody may recognize sAPPα (this fragment contains Aβ1-17), and the anti-APP (KPI domain) antibody may recognize both sAPPα and sAPPβ on immunoblot. The result showed that 6E10 antibody-recognized sAPPα was not significantly affected by the fractions of F. macrophylla. By contrast, the anti-APP (KPI domain) antibody-recognized sAPPα and sAPPβ were significantly decreased. The fractions of EtOH, EA-47, and B50M decreased the level of sAPPs to %, %, and %, respectively. The result indicated that the fractions may inhibit the activity of β-secretase and then decrease the level of sAPPβ (Figure 7), which may reflect the effects of these fractions on attenuating Aβ accumulation.
It is generally believed that removal of Aβ from the brain might be of great benefit for AD therapy [14, 23]. To find the reagents which are capable of reducing Aβ levels is required for improving the treatment of AD. Aβ level are determined by the metabolic balance between anabolic and catabolic activities. Among the catabolic enzymes, insulin degrading enzyme (IDE) is thought to be the principal secreted enzyme responsible for the degradation of Aβ in the extracellular space [18, 21, 24]. An interesting link between insulin and Aβ is that they both are IDE substrates [20, 25, 26], and the patients with type 2 diabetes have an increased risk of AD . Since IDE is more efficient on degrading insulin than Aβ, the concomitant increase in insulin and Aβ levels may lead to a redistribution of available IDE away from its function as an Aβ-degrading enzyme . Thus, the involvement of IDE on Aβ degradation in our experimental system was verified by insulin and bacitracin, an IDE competitive inhibitor , to promote Aβ accumulation. Aβ degradation was completely abolished by 1 μM Insulin, which was only partially inhibited by bacitracin. The results suggesting that IDE may be the major enzyme contribute to degrade the extracellular Aβ.
By using swAPP-N2a as cell model, we investigated the effects of F. macrophylla on reducing Aβ accumulation in the present of 100 nM insulin. Previous studies have indicated that some herbal medicine-derived compounds reduced Aβ accumulation in the similar cell models [29–33]. F. macrophylla is a popular traditional remedy used in Taiwan  and India . The stems have been used in folk medicine for antirheumatic and anti-inflammatory agent, promoting blood circulation and antidiabetes. Our recent research has suggested the AD-relative neuroprotective effects of F. macrophylla on the primary cultures of neonatal cortical neurons against Aβ-mediated neurotoxicity . However, the effect of F. macrophylla on Aβ accumulation and the underlying mechanism has not been studied. To investigate whether F. macrophylla affects Aβ metabolism, we detect the extracellular and intracellular Aβ1-40 levels of the treated swAPP-N2a cells by ELISA assay and found that fraction EtOH, EA-74, and B50M and flavonoid 49-3, 52-11, and 94-19-13 significantly reduced the extracellular Aβ1-40 accumulation without promoting the intracellular Aβ1-40 accumulation.
Several target sites including Aβ anabolic, trafficking, and catabolic pathways could be considered as the targets of the fractions or flavonoids on Aβ accumulation in swAPP-N2a cells. Therefore, a cell-free Aβ degradation system using N2a cell-conditioned medium as protease source and the synthetic Aβ1-40 as subtract was used to bypass the involvement of Aβ anabolic and trafficking pathway. The results showed that Aβ degradation was inhibited by insulin in a concentration-dependent manner. Aβ degradation was completely abolished by 1 μM insulin. Bacitracin partially inhibited the degradation of Aβ1-40 alone or combined with insulin. It has been proposed that both microglia and astrocytes secrete protease, including IDE that mediates the degradation of Aβ in the extracellular milieu [21, 34] which may be similar to our system.
Aβ degradation by IDE was promoted by the fractions and flavonoids. In the presence of 100 nM insulin, the fractions and flavonoids decreased the remaining Aβ1-40 to about 80% of the control. The results suggest that the fractions and flavonoids may ameliorate Aβ accumulation by promoting Aβ degradation.
To study the mechanism underlying the effect of the fractions and flavonoids on the level of IDE, we first performed western blot analysis to detect IDE expression. The results showed that only flavonoid 94-18-13 significantly improved IDE expression. Nevertheless, the underlying mechanism required further investigation, although recent studies have indicated that IDE expression may be regulated through liver X receptor , NMDA receptor , β2 adrenergic receptor , insulin receptor , dopamine receptor , and glucocorticoid receptor .
To study the effect of the fractions and compounds on the IDE-dependent degradation pool of extracellular Aβ, we then detected extracellular Aβ1-40 levels with ELISA after treating swAPP-N2a cells with the fractions or flavonoids in the absence or presence of 2 nM bacitracin. We found that three fractions and flavonoid 94-19-13 activated IDE without affecting the bacitracin-sensitive pool, which was partially compressed and extended by flavonoid 49-3 and 52-11, respectively, through the allosteric regulatory effect. In the previous study, Cabrol et al.  discovered two small molecule activators of IDE through high-throughput compound screening. They established the putative ATP-binding domain as a key modulator of IDE proteolytic activity. ATP inhibits IDE-mediated insulin degradation at physiological concentration . On the other hand, ATP was found to activate IDE-mediated fluorogenic substrate by conformational switch through its triphosphate moiety [43, 44]. Recently, the allosteric regulatory sites of IDE were identified . Therefore, the fractions and flavonoids may activate IDE by occupying the allosteric binding site.
To determine whether the fractions affect Aβ anabolism, the western blot of medial sAPPs (sAPPα and sAPPβ) was performed. The results showed that all three fractions ameliorated the production of sAPPs but not sAPPα, suggesting that sAPPβ was affected by these three fractions through inhibiting the activity of β-secretase. The previous studies have demonstrated that the tenuigenin isolated from Polygala tenuifolia and berberine isolated from Coptidis rhizome can inhibit the secretion of Aβ via β-secretase inhibition [30–32].
The results suggested that the fraction EtOH, EA-74, and B50M of F. macrophylla may modify Aβ accumulation by both inhibiting β-secretase and activating IDE. The three flavonoids may modify Aβ accumulation by activating IDE. The activated IDE poor by these three flavonoids was distinctly regulated by bacitracin. Furthermore, flavonoid 94-18-13 also modulates Aβ accumulation by enhancing IDE expression. Change in Aβ accumulation may prevent Aβ aggregation and the subsequent neurotoxicity on AD. Such information could be exploited to develop the new therapeutic drugs for sporadic AD.
This study was supported by Grant no. NSC-97-2320-B-077-003-MY3 from National Science Council, Grant no, NRICM-98-DBCM-06 from National Research Institute of Chinese Medicine, Taiwan, and the Ministry of Education-Aim for the Top University Plan (010AC-B5).
- T. C. Huang and H. Ohashi, “Leguminosae,” in Flora of Taiwan, vol. 3, pp. 160–396, Editorial Committee of Flora of Taiwan, Taipei, Taiwan, 2nd edition, 1993.
- D. Syiem and P. Z. Khup, “Evaluation of Flemingia macrophylla L., a traditionally used plant of the north eastern region of India for hypoglycemic and anti-hyperglycemic effect on mice,” Pharmacologyonline, vol. 2, pp. 355–366, 2007.
- Y. J. Shiao, C. N. Wang, W. Y. Wang, and Y. L. Lin, “Neuroprotective flavonoids from Flemingia macrophylla,” Planta Medica, vol. 71, no. 9, pp. 835–840, 2005.
- P. C. Hsieh, Y. L. Ho, G. J. Huang et al., “Hepatoprotective effect of the aqueous extract of Flemingia macrophylla on carbon tetrachloride-induced acute hepatotoxicity in rats through anti-oxidative activities,” American Journal of Chinese Medicine, vol. 39, no. 2, pp. 349–365, 2011.
- Y. J. Ko, T. C. Lu, S. Kitanaka et al., “Analgesic and anti-inflammatory activities of the aqueous extracts from three flemingia species,” American Journal of Chinese Medicine, vol. 38, no. 3, pp. 625–638, 2010.
- W. C. Lin, H. Y. Ho, and J. B. Wu, “Flemingia macrophylla extract ameliorates experimental osteoporosis in ovariectomized rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 752302, 9 pages, 2011.
- D. J. Selkoe, “Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid β-protein,” Journal of Alzheimer's Disease, vol. 3, no. 1, pp. 75–81, 2001.
- M. Citron, “β-Secretase inhibition for the treatment of Alzheimer's disease-promise and challenge,” Trends in Pharmacological Sciences, vol. 25, no. 2, pp. 92–97, 2004.
- M. P. Mattson, “Pathways towards and away from Alzheimer's disease,” Nature, vol. 430, no. 7000, pp. 631–639, 2004.
- G. K. Gouras, D. Tampellini, R. H. Takahashi, and E. Capetillo-Zarate, “Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer's disease,” Acta Neuropathologica, vol. 119, no. 5, pp. 523–541, 2010.
- O. Isacson, H. Seo, L. Lin, D. Albeck, and A. C. Granholm, “Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh,” Trends in Neurosciences, vol. 25, no. 2, pp. 79–84, 2002.
- L. Gasparini, W. J. Netzer, P. Greengard, and H. Xu, “Does insulin dysfunction play a role in Alzheimer's disease?” Trends in Pharmacological Sciences, vol. 23, no. 6, pp. 288–293, 2002.
- R. A. Nixon, “Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases,” Neurobiology of Aging, vol. 26, no. 3, pp. 373–382, 2005.
- K. A. Bates, G. Verdile, Q. X. Li et al., “Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests,” Molecular Psychiatry, vol. 14, no. 5, pp. 469–486, 2009.
- A. K. Ghosh, S. Gemma, and J. Tang, “β-secretase as a therapeutic target for Alzheimer's disease,” Neurotherapeutics, vol. 5, no. 3, pp. 399–408, 2008.
- M. S. Wolfe, “Inhibition and modulation of γ-secretase for Alzheimer's disease,” Neurotherapeutics, vol. 5, no. 3, pp. 391–398, 2008.
- C. A. Lemere and E. Masliah, “Can Alzheimer disease be prevented by amyloid-β immunotherapy?” Nature Reviews Neurology, vol. 6, no. 2, pp. 108–119, 2010.
- J. S. Miners, S. Baig, J. Palmer, L. E. Palmer, P. G. Kehoe, and S. Love, “Aβ-degrading enzymes in Alzheimer's disease,” Brain Pathology, vol. 18, no. 2, pp. 240–252, 2008.
- J. S. Roriz-Filho, T. M. Sá-Roriz, I. Rosset et al., “(Pre)diabetes, brain aging, and cognition,” Biochimica et Biophysica Acta, vol. 1792, no. 5, pp. 432–443, 2009.
- W. Q. Qiu and M. F. Folstein, “Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis,” Neurobiology of Aging, vol. 27, no. 2, pp. 190–198, 2006.
- W. Q. Qiu, D. M. Walsh, Z. Ye et al., “Insulin-degrading enzyme regulates extracellular levels of amyloid β- protein by degradation,” Journal of Biological Chemistry, vol. 273, no. 49, pp. 32730–32738, 1998.
- A. Perez, L. Morelli, J. C. Cresto, and E. M. Castano, “Degradation of soluble amyloid beta-peptides 1–40, 1–42, and the Dutch variant 1–40Q by insulin degrading enzyme from Alzheimer disease and control brains,” Neurochem Research, vol. 25, no. 2, pp. 247–255, 2000.
- M. S. Forman, J. Q. Trojanowski, and V. M. Y. Lee, “Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs,” Nature Medicine, vol. 10, no. 10, pp. 1055–1063, 2004.
- W. Farris, S. Mansourian, Y. Chang et al., “Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 7, pp. 4162–4167, 2003.
- G. Taubes, “Insulin insults may spur Alzheimer's disease,” Science, vol. 301, no. 5629, pp. 40–41, 2003.
- W. Farris, S. Mansourian, M. A. Leissring et al., “Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid β-protein,” American Journal of Pathology, vol. 164, no. 4, pp. 1425–1434, 2004.
- G. S. Watson, E. R. Peskind, S. Asthana et al., “Insulin increases CSF Aβ42 levels in normal older adults,” Neurology, vol. 60, no. 12, pp. 1899–1903, 2003.
- T. Shiiki, S. Ohtsuki, A. Kurihara et al., “Brain insulin impairs amyloid-β(1–40) clearance from the brain,” Journal of Neuroscience, vol. 24, no. 43, pp. 9632–9637, 2004.
- H. Y. Zhang, H. Yan, and X. C. Tang, “Huperzine A enhances the level of secretory amyloid precursor protein and protein kinase C-α in intracerebroventricular β-amyloid-(1–40) infused rats and human embryonic kidney 293 Swedish mutant cells,” Neuroscience Letters, vol. 360, no. 1-2, pp. 21–24, 2004.
- H. Jia, Y. Jiang, Y. Ruan et al., “Tenuigenin treatment decreases secretion of the Alzheimer's disease amyloid β-protein in cultured cells,” Neuroscience Letters, vol. 367, no. 1, pp. 123–128, 2004.
- J. Lv, H. Jia, Y. Jiang et al., “Tenuifolin, an extract derived from tenuigenin, inhibits amyloid-β secretion in vitro,” Acta Physiologica, vol. 196, no. 4, pp. 419–425, 2009.
- M. Asai, N. Iwata, A. Yoshikawa et al., “Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease Aβ secretion,” Biochemical and Biophysical Research Communications, vol. 352, no. 2, pp. 498–502, 2007.
- L. Yang, J. Hao, J. Zhang et al., “Ginsenoside Rg3 promotes beta-amyloid peptide degradation by enhancing gene expression of neprilysin,” Journal of Pharmacy and Pharmacology, vol. 61, no. 3, pp. 375–380, 2009.
- I. V. Kurochkin and S. Goto, “Alzheimer's β-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme,” FEBS Letters, vol. 345, no. 1, pp. 33–37, 1994.
- Q. Jiang, C. Y. D. Lee, S. Mandrekar et al., “ApoE promotes the proteolytic degradation of Aβ,” Neuron, vol. 58, no. 5, pp. 681–693, 2008.
- J. Du, J. Chang, S. Guo, Q. Zhang, and Z. Wang, “ApoE 4 reduces the expression of Aβ degrading enzyme IDE by activating the NMDA receptor in hippocampal neurons,” Neuroscience Letters, vol. 464, no. 2, pp. 140–145, 2009.
- Y. Kong, L. Ruan, L. Qian, X. Liu, and Y. Le, “Norepinephrine promotes microglia to uptake and degrade amyloid β peptide through upregulation of mouse formyl peptide receptor 2 and induction of insulin-degrading enzyme,” Journal of Neuroscience, vol. 30, no. 35, pp. 11848–11857, 2010.
- D. Luo, X. Hou, L. Hou et al., “Effect of pioglitazone on altered expression of Aβ metabolism-associated molecules in the brain of fructose-drinking rats, a rodent model of insulin resistance,” European Journal of Pharmacology, vol. 664, no. 1–3, pp. 14–19, 2011.
- E. Himeno, Y. Ohyagi, L. Ma et al., “Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation,” Annals of Neurology, vol. 69, no. 2, pp. 248–256, 2011.
- Y. Wang, M. Li, J. Tang et al., “Glucocorticoids facilitate astrocytic amyloid-β peptide deposition by increasing the expression of APP and BACE1 and decreasing the expression of amyloid-β-degrading proteases,” Endocrinology, vol. 152, no. 7, pp. 2704–2715, 2011.
- C. Cabrol, M. A. Huzarska, C. Dinolfo et al., “Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening,” PloS one, vol. 4, no. 4, p. e5274, 2009.
- M. C. Camberos, A. A. Pérez, D. P. Udrisar, M. I. Wanderley, and J. C. Cresto, “ATP inhibits insulin-degrading enzyme activity,” Experimental Biology and Medicine, vol. 226, no. 4, pp. 334–341, 2001.
- E. S. Song, M. A. Juliano, L. Juliano, M. G. Fried, S. L. Wagner, and L. B. Hersh, “ATP effects on insulin-degrading enzyme are mediated primarily through its triphosphate moiety,” Journal of Biological Chemistry, vol. 279, no. 52, pp. 54216–54220, 2004.
- H. Im, M. Manolopoulou, E. Malito et al., “Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE,” Journal of Biological Chemistry, vol. 282, no. 35, pp. 25453–25463, 2007.
- N. Noinaj, S. K. Bhasin, E. S. Song et al., “Identification of the allosteric regulatory site of insulysin,” PLoS ONE, vol. 6, no. 6, Article ID e20864, 2011.